Today: 15 June 2026
Browse Category

NASDAQ:BEAM 20 October 2025 - 4 June 2026

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
4 June 2026
·······
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
Beam Therapeutics stock rises 5% after BofA lifts target to $45

Beam Therapeutics stock rises 5% after BofA lifts target to $45

Beam Therapeutics shares rose about 5% to $28.24 by early afternoon Tuesday after Bank of America raised its price target to $45 and reaffirmed a buy rating. The stock touched $30.49 before paring gains. A new SEC filing showed Chief Legal Officer Christine Bellon sold 1,254 shares on Dec. 31 in an automatic transaction tied to tax withholding.
6 January 2026
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

ARK Invest bought 521,867 Pinterest shares across three funds after the stock fell over 20% on weak holiday-quarter guidance. The firm also added CRISPR Therapeutics and Beam Therapeutics shares earlier in the week. ARK sold 105,576 Roku shares and 56,095 Robinhood shares, and reduced its position in Teradyne. Pinterest projected Q4 revenue below consensus, citing softer ad spending and tougher competition.
6 November 2025
········
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

The FDA will announce a new fast-track approval process for personalized gene-editing therapies in early November, sending CRISPR Therapeutics shares up 8% and Editas up 12%. CRSP reported over 90% mRNA correction in preclinical CTX460 data and will present Phase 1 CTX310 results at the AHA conference Nov. 8. Intellia paused a TTR amyloidosis trial after a liver injury, causing its stock to fall 46%.
2 November 2025
······
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics shares rose about 17% to $30 after the FDA granted RMAT and Orphan Drug designations to its lead gene-editing programs, BEAM-101 and BEAM-302. Early trial data showed BEAM-302 raised protective AAT levels and BEAM-101 produced durable increases in fetal hemoglobin. Wall Street’s average 12-month price target is $45–46, implying roughly 70–80% upside.
21 October 2025
··
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics shares jumped 17% to $30.35 on Oct. 20, 2025, marking their highest level since early 2024. The rally followed bullish technical signals and positive clinical updates for its gene-editing therapies. Analysts at Jefferies and H.C. Wainwright reiterated Buy ratings, with price targets up to $80. Beam ended Q2 with $1.2 billion in cash, enough to fund operations into 2028.
20 October 2025
·····

Stock Market Today

  • Hellenic Telecomms Buys Back 121,088 Shares Under 2026 Buyback Program
    June 15, 2026, 3:31 AM EDT. Hellenic Telecommunications Organization S.A. (OTE) purchased 121,088 of its own shares between June 8 and June 12, 2026, as part of its 2026 Own Share Buy Back Programme. The shares were acquired at an average price of €18.26 each, totaling approximately €2.21 million. After this transaction, OTE holds 10.94 million treasury shares, representing 2.709% of its total outstanding shares. This activity complies with EU regulations governing market transparency. OTE maintains communication with investors via its investor relations office.

Latest articles

Dow Futures Tick Up, Oil Drops After U.S.-Iran Deal, SpaceX IPO in Focus

Dow Futures Tick Up, Oil Drops After U.S.-Iran Deal, SpaceX IPO in Focus

15 June 2026
Dow, S&P 500, and Nasdaq futures rose Sunday evening after reports of a U.S.-Iran peace deal that would reopen the Strait of Hormuz, sending oil prices down over 4% as traders anticipated resumed energy shipments; SpaceX shares surged 19.2% in their Nasdaq debut, closing at $160.95 and pushing market cap above $2 trillion, while investors await confirmation of the deal and details on shipping normalization.
Asia Opens June 16 as Oil Gains, BOJ and Fed Moves Loom

Asia Opens June 16 as Oil Gains, BOJ and Fed Moves Loom

15 June 2026
Brent crude plunged 4.02% to $83.82 and WTI fell 4.63% to $80.95 after the U.S. and Iran reached a deal to halt the war and reopen the Strait of Hormuz, easing inflation pressure and lifting profit expectations for Asian equities, but execution risks remain with the deal’s terms incomplete and potential for oil to rebound if tensions flare. (Reuters)
Fed, Oil Prices, and SpaceX Draw Attention Prior to Tuesday’s Open

Fed, Oil Prices, and SpaceX Draw Attention Prior to Tuesday’s Open

15 June 2026
U.S. stocks face key risks as investors await the June 16–17 Fed meeting, with inflation at 4.2% and Brent crude at $86.80; the U.S.-Iran deal could lower oil prices and ease inflation, but uncertainty over terms and Fed policy keeps markets volatile, while SpaceX’s 19.2% Nasdaq debut signals strong demand for AI-linked growth stocks. (Reuters)
Go toTop